{
    "clinical_study": {
        "@rank": "127743", 
        "arm_group": {
            "arm_group_label": "Remifentanil IV PCA", 
            "arm_group_type": "Other"
        }, 
        "brief_summary": {
            "textblock": "Determine effects of remifentanil conscious sedation in patients undergoing\n      Electrophysiological (EP) studies for the ablation of idiopathic ventricular tachycardia\n      and/or persistent frequent PVCs of non-ischemic origin"
        }, 
        "brief_title": "Remifentanil IV PCA for Ablation of Idiopathic Ventricular Tachycardia", 
        "completion_date": {
            "#text": "April 2013", 
            "@type": "Actual"
        }, 
        "condition": "Tachycardia, Ventricular", 
        "condition_browse": {
            "mesh_term": [
                "Tachycardia", 
                "Tachycardia, Ventricular"
            ]
        }, 
        "detailed_description": {
            "textblock": "The purpose of the study is to determine the effects of remifentanil conscious sedation in\n      patients undergoing Electrophysiological (EP) studies for the ablation of idiopathic\n      ventricular tachycardia and/or persistent frequent PVCs of non-ischemic origin.\n\n      Remifentanil is an analgesic- synthetic opiate with an very short half life. It is rapidly\n      broken down by enzymes in the blood and is ideally suited for continuous sedation. The\n      effect is practically eliminated within 5 minutes after the intravenous sedation is stopped.\n\n      You are being asked to participate in this study because you are already scheduled to\n      undergo EP studies under the care of your cardiologist for the ablation of idiopathic\n      ventricular tachycardia and/or persistent frequent PVCs of non-ischemic origin."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients scheduled to undergo EP studies for the ablation of idiopathic ventricular\n             tachycardia and/or persistent frequent PVCs of non-ischemic origin\n\n          -  Patients between 18 and 65\n\n          -  ASA 1-3\n\n        Exclusion Criteria:\n\n          -  ASA 4 and 5\n\n          -  Age 18 and 65"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "25", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01901575", 
            "org_study_id": "11-00800"
        }, 
        "intervention": {
            "arm_group_label": "Remifentanil IV PCA", 
            "intervention_name": "Remifentanil", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Remifentanil"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "ideopathic ventricular tachycardia", 
        "lastchanged_date": "July 12, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10016"
                }, 
                "name": "NYU Langone Medical Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Remifentanil IV PCA for Ablation of Idiopathic Ventricular Tachycardia", 
        "overall_official": {
            "affiliation": "NYU School of Medicine", 
            "last_name": "Misha Kogan, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "observation of the anesthetic effect on the inhibition of the ventricular tachycardia in patients undergoing radio-frequency ablation of idiopathic ventricular tachycardia (RV0T)", 
            "measure": "Inhibition of idiopathic ventricular tachycardia", 
            "safety_issue": "No", 
            "time_frame": "during procedure"
        }, 
        "reference": {
            "PMID": "18783026", 
            "citation": "Garofalo NA, Teixeira-Neto FJ, Schwartz DS, Vailati Mdo C, Steagall PV. Effects of the opioid remifentanil on the arrhythmogenicity of epinephrine in halothane-anesthetized dogs. Can J Vet Res. 2008 Jul;72(4):362-6."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01901575"
        }, 
        "responsible_party": {
            "investigator_affiliation": "New York University School of Medicine", 
            "investigator_full_name": "Avrimin M Kogan, MD", 
            "investigator_title": "Clinical Assistant Professo", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "New York University School of Medicine", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "New York University School of Medicine", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2011", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}